<DOC>
	<DOCNO>NCT00912574</DOCNO>
	<brief_summary>Goal : To characterize cellular event occur vivo vaccination emulsion GMCSF-in-adjuvant . Design : Open-label , single dose study two stage .</brief_summary>
	<brief_title>Evaluation Effects Local Granulocyte-Macrophage Colony-Stimulating Factor ( GM-CSF ) Adjuvant Administration Dendritic Cells Skin Melanoma Patients Sentinel Lymph Nodes : MEL38</brief_title>
	<detailed_description>Regimen : Each injection administer patient clinical stage I II melanoma , complete excision primary melanoma , prior wide excision without sentinel node biopsy definitive surgical therapy . In Stage 1 : Patients inject 1 ml emulsion contain GM-CSF saline plus Montanide ISA-51 adjuvant , skin adjacent melanoma biopsy scar . In Stage 2 : Patients randomize receive injection one follow skin adjacent melanoma biopsy scar : 1 . 1 ml saline 2 . GM-CSF 1 ml saline 3. emulsion Montanide ISA-51 adjuvant saline 4. emulsion GM-CSF saline plus ml Montanide ISA-51 adjuvant . All vaccine administer intradermally . After injection , patient undergo wide excision melanoma site , without sentinel node biopsy , clinically indicate .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Patients diagnose , histologic clinical examination , resect AJCC stage I II melanoma . Patients evidence metastasis eligible . All patient must : 1 . Karnofsky performance 80 % high 2 . ECOG performance status 0 1 3 . Ability willingness give inform consent Laboratory parameter follow : 1 . ANC : 90 % low limit normal ( LLN ) 120 % upper limit normal ( ULN ) 2 . Platelets : 100500 x 103/uL 3 . Hgb : 90 % LLN 120 % ULN 4 . Hepatic : 1 . AST , ALT , Bilirubin , Alk phos within normal limit , 2 . LDH 1.2 x ULN 5 . Renal : 1 . Creatinine 1.5 x ULN Age 1885 year time study entry . Patients currently receive cytotoxic chemotherapy , interferon , radiation receive therapy within precede 12 week . Patients know suspected allergy component vaccine . Patients receive follow medication study entry within precede 4 week exclude : Agents putative immunomodulating activity ( exception nonsteroidal antiinflammatory agent ) , Allergy desensitization injection , Corticosteroids , administer parenterally orally . Topical corticosteroid acceptable . Any growth factor , Interleukin2 interleukins . Pregnancy possibility become pregnant vaccine administration . Female patient childbearing potential must negative pregnancy test ( urinary serum betaHCG ) prior administration injection . Patients medical contraindication potential problem complying requirement protocol , opinion investigator . Patients classify accord New York Heart Association classification Class III IV heart disease . Patients serious symptomatic active pulmonary disease , pleural effusion , history pulmonary edema . Patients systemic autoimmune disease visceral involvement . Patients clinically apparent skin infection clinically evident inflammation involve skin adjacent melanoma biopsy scar .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>adjuvant</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>vaccine</keyword>
</DOC>